3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 116 points (0.8%) at 15,038 as of Monday, Sept. 9, 2013, 12:44 PM ET. The NYSE advances/declines ratio sits at 2,262 issues advancing vs. 646 declining with 106 unchanged.

The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 11.5%, Incyte ( INCY), up 5.5% and Novo Nordisk A/S ( NVO), up 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Sanofi ( SNY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.46 (-0.9%) to $48.30 on light volume. Thus far, 508,811 shares of Sanofi exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $47.93-$48.37 after having opened the day at $48.09 as compared to the previous trading day's close of $48.76.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $127.5 billion and is part of the health care sector. Shares are up 2.9% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.31 (-0.8%) to $38.23 on light volume. Thus far, 1.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $38.02-$38.50 after having opened the day at $38.45 as compared to the previous trading day's close of $38.54.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.7 billion and is part of the health care sector. Shares are up 3.2% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Allergan ( AGN) is down $0.76 (-0.8%) to $88.45 on light volume. Thus far, 425,923 shares of Allergan exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $88.36-$89.41 after having opened the day at $89.36 as compared to the previous trading day's close of $89.21.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.4 billion and is part of the health care sector. Shares are down 2.7% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

With GE Dropped From the Dow, Be Selective About Industrials Stocks

With GE Dropped From the Dow, Be Selective About Industrials Stocks

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

Dow Rises as Blue-Chip Index Looks to End Losing Streak

Dow Rises as Blue-Chip Index Looks to End Losing Streak

3 Things to Know About the New Head of Amazon's Joint Stab at U.S. Healthcare

3 Things to Know About the New Head of Amazon's Joint Stab at U.S. Healthcare